It is well-known that the pregnant state is associated with increased sensitivity to endotoxin in renal and uterine circulations; however, the effects on the cerebral circulation are not known. Intravenous infusion of low-dose lipopolysaccharide ([LPS]; 1.5 mg/kg) to pregnant Wistar rats on day 15 of pregnancy caused significantly decreased myogenic tone of posterior cerebral arteries on day 20, which was not seen in similarly treated nonpregnant rats. Pregnancy alone was associated with a 2-to 4-fold increase in inducible nitric oxide synthase (iNOS), tumor necrosis factor-a (TNF-a), and interferon-g (IFN-g) messenger RNA (mRNA) in cerebral arteries compared to nonpregnant, suggesting that the cerebral circulation is in a state of inflammation during pregnancy. After LPS treatment, cerebral arteries from pregnant animals had increased iNOS and TNF-a compared to LPStreated nonpregnant animals, but decreased interleukin 10 (IL-10) and IFN-g. These results demonstrate that pregnancy enhances sensitivity to the effects of LPS in the cerebral circulation, which may be due to an enhanced inflammatory state during pregnancy.
Introduction
It is well established that pregnant animals and humans are more sensitive to bacterial endotoxin than nonpregnant. [1] [2] [3] For example, low-dose endotoxin administration to pregnant rats causes a generalized Shwartzman reaction, including disseminated intravascular coagulation, which is not seen in similarly treated nonpregnant rats. [3] [4] [5] In addition, low-dose endotoxin causes an inflammatory response in pregnant rats that is significantly more intense and persistent than in nonpregnant animals and includes an increase in the number of activated immune cells and upregulation of adhesion molecules. 5 This increased sensitivity to endotoxin during pregnancy reflects one aspect of immune competence changes that allow tolerance of the fetal allograft. However, changes in both innate and adaptive maternal immunity occur that are important for many aspects of reproduction, including implantation, placental development, and parturition. [6] [7] [8] In addition, changes in immune system function during pregnancy have been linked to pathological conditions such as preterm birth and preeclampsia. 9, 10 While modulation of the maternal immune system is complex and not completely understood, an exaggerated peripheral inflammatory response during pregnancy could have significant consequences for the brain. Although the brain has long been considered an immunoprivileged organ due to the protective role of the cerebral endothelium that forms the blood-brain barrier (BBB), recent studies have shown that peripheral inflammation promotes inflammatory events in the brain. For example, inflammatory bowel disease and hepatic inflammation have been associated with the appearance of an inflammatory response in the brain characterized by upregulation of endothelial cell adhesion molecules in the BBB, activation of glial cells, and production of proinflammatory cytokines that increases seizure susceptibility. 11, 12 Similar neurological complications occur during preeclampsia and eclampsia that may be related to peripheral immune system activation. For example, in both women with preeclampsia and low-dose endotoxin-treated pregnant rats, circulating leukocytes have an activated phenotype and increased production of reactive oxygen species. 13 If similar inflammatory events occur in the brain and BBB, including upregulation of adhesion molecules and production of proinflammatory cytokines, the result could promote neurological complications, including seizure.
One target of local inflammatory events is the vasculature. Activated peripheral tissue macrophages release proinflammatory cytokines, such as tumor necrosis factor-a (TNF-a) and interferon-g (IFN-g), which act on endothelial cells to upregulate adhesion molecules and produce chemokines that promote passage of leukocytes through endothelial cells where they can act at the site of injury or infection. 14, 15 In addition, vascular cells both produce and respond to cytokines that alter vascular structure and function. 16, 17 In particular, the cerebral circulation has a central role in the neurological complications of preeclampsia and eclampsia, yet how this circulation responds to innate immune system activation during pregnancy, including production of cytokines, is not known. In the present study, we used a model of low-dose endotoxin during pregnancy to investigate how peripheral immune activation affects the structure and function of the cerebral circulation, including diameter regulation and the role of inducible nitric oxide synthase (iNOS) in mediating vasodilation. In addition, we investigated how pregnancy and peripheral immune system activation during pregnancy affected the expression of proinflammatory (TNF-a and IFN-g) and anti-inflammatory (interleukin 10 [IL-10]) cytokines within the cerebral vascular wall.
Materials and Methods Animals
All animal procedures were approved by the Institutional Animal Care and Use Committee at the University of Vermont and performed in accordance with the National Institutes of Health Policy on the care and use of laboratory animals. Timed-pregnant Wistar rats were purchased (Harlan) and housed in the animal care facility at the University of Vermont. Age-matched nonpregnant virgin female Wistar rats were used as controls. Animals were kept in a 12-hour light, 12-hour dark cycle, and allowed food and water ad libitum. Separate sets of both pregnant and nonpregnant animals were infused with a microdose of lipopolysaccharide (LPS) to active the innate immune system. Control animals were infused with sterile saline solution for the same duration. Briefly, on day 15 of pregnancy (or 5 days prior to use for nonpregnant rats), animals were anesthetized with isoflurane in oxygen and a catheter placed into the jugular vein. Lipopolysaccharide (1.5 mg/kg) dissolved in a 2-mL sterile saline solution or saline alone (vehicle-treated) was infused for 1 hour after which the catheter was removed and the incision closed with 4-O suture. The animals were allowed to recover and used for experimentation 5 which was on days 19 
Blood Pressure Measurements
All animals had blood pressure measurements taken prior to and the day after surgery, as well as on the day of experimentation. Blood pressures were taken noninvasively using a tail cuff method (CODAS 8, Kent Scientific, Torrington, Connecticut), as described previously. 18 Briefly, animals were placed in individual holders, and both an occlusion cuff and a volume pressure-recording cuff were placed close to the base of the tail. Volume pressure recording allowed the noninvasive measurement of 6 blood pressure parameters simultaneously: systolic blood pressure, diastolic blood pressure, mean blood pressure, heart pulse rate, tail blood volume, and tail blood flow.
Messenger RNA Expression of iNOS, TNF-a, IFN-g, and IL-10 in the Cerebral Vasculature by (PCR) Expression of cytokine messenger RNA (mRNA) in cerebral arteries was determined using standard techniques for real-time quantitative polymerase chain reaction (qPCR) and was performed by the DNA Facility at the University of Vermont, as described previously. 19 Briefly, cerebral arteries were dissected from the brain separately from each group of animal and rapidly frozen in RNA later. The vessels were then removed and placed in an RNase-free microcentrifuge tube, homogenized in the presence of RLT Buffer, and total RNA isolated using an RNeasy Micro Kit (Qiagen, Valencia, California) animal tissue protocol. To increase yield, samples were not DNAase treated and arteries from 2 to 3 animals were pooled. The concentration of total RNA was obtained from a NanoDrop ND-1000 Spectrophotometer (Wilmington, Delaware) and its integrity analyzed by an Agilent 2100 Bioanalyzer (Santa Clara, California). Complementary DNA (cDNA) was made from total RNA using SuperScript 14 Kit (Invitrogen, Carlsbad, California). The cDNA reaction was performed according to the standard protocol, using random hexamers and 4.8 ng of total RNA. Real-time PCR was set up as follows: 10:1 Universal PCR Master Mix (Applied Biosystems, Foster City, California), 1:1 Assay on Demand (Applied Biosystems), and 8:1 water, 1:1 cDNA. All target genes (IL-10, TNF-a, IFN-g, and iNOS and B2m for an endogenous control) were assessed using Assays on Demand from Applied Biosystems that were validated for efficiency and did not amplify genomic DNA. All samples were run in technical duplicates using a 7900HT Sequence Detection System (Applied Biosystems). The PCR was cycled for 2 minutes at 50 C, 10 minutes at 95 C, then 40 cycles at 95 C for 15 seconds, and 60 C for 1 minute. Only threshold cycle (Ct) duplicate values of <35 were used (if replicates were >1.0 apart, they were rerun). Ct values were averaged and used for comparison using the DDCt method. 20 Relative quantification (RQ) values were determined by first calculating the DCt (difference between target gene Ct and endogenous control gene Ct) and the DDCt (difference between Cts to be compared). Relative quantification value was then calculated as 2 ÀDDCt .
Isolated Artery Experiments and Arteriograph System
On the day of tissue harvest, animals were deeply anesthetized with isoflurane and decapitated. The brain was quickly removed and placed in cold, physiological salt solution (PSS). A third-order branch of the posterior cerebral artery (PCA) was carefully dissected and cleared of connective tissue. The arteries were mounted on a glass cannulas within an arteriograph chamber (Living Systems Instrumentation, Burlington, Vermont) and perfused and superfused with PSS, as described previously. 18, 19 Physiological salt solution was maintained at pH 7.40 + 0.05 by aeration (see below) and warmed to 37 C for the entire experiment. The proximal cannula of the arteriograph was connected to an in-line pressure transducer and servo controller that maintained intravascular pressure at a set pressure or changed at a variable rate. The arteriograph contained an optical window on the bottom of the chamber that allowed for continuous measurement of lumen diameter and wall thickness via video microscopy.
Experimental Protocol
Arteries were equilibrated for 1 hour at 50 mm Hg after which pressure was increased stepwise in 25 mm Hg steps to 150 mm Hg. Active lumen diameter and wall thickness were recorded at each pressure once stable, approximately 10 minutes. Once active pressure versus diameter curves was completed, pressure was returned to 75 mm Hg for the remainder of the experiment. This pressure was chosen because this is approximately the pressure these arteries operate at in vivo. 21 A single high concentration (0.1 mmol/L) of the NOS inhibitor L-nitro-arginine (L-NNA) was then added to the bath and constriction in response to NOS inhibition measured. This is a common means to assess the contribution of NO to basal tone of arteries. 19, 22, 23 After approximately 20 minutes in L-NNA, the NO donor diethylenetriamine NONOate was cumulatively added to the bath (1 nmol/L-1 mmol/L) and the dilation to NO was determined. At the end of the experiment, papaverine (0.1 mmol/ L) and diltiazem (10 À5 mol/L) were added to the bath to obtain fully relaxed diameters. Passive diameters and wall thicknesses were then recorded over a wide pressure range to obtain structural measurements, including distensibility.
Drugs and Solutions
All experiments were conducted using Kreb's PSS (a bicarbonate-based buffer aerated with 5% CO 2 , 10% O 2 , and 85% N 2 to maintain pH), the ionic composition was (mmol/ L): NaCl 119.0, NaHCO 3 24.0, KCl 4.7, KH 2 PO 4 1.18, MgSO 4 Á7H 2 O 1.17, CaCl 2 1.6, EDTA 0.026, and glucose 5.5. Physiological salt solution was made each week and stored without glucose at 4 C; glucose was added to the PSS prior to each experiment. Both L-NNA and NONOate were purchased from Sigma and stored as stock solutions made fresh each week.
Data Calculations
Vascular tone was calculated as a percent decrease in diameter from the fully relaxed diameter in papaverine by the equation:
Percent constriction to L-NNA was calculated as a percent decrease in diameter from baseline by the equation: (1À[f l-
Percent distensibility was calculated at each pressure in fully relaxed vessels in papaverine by determining diameter changes as a function of pressure. The following equation was used: ([f pressure /f 5 mm Hg ]À1) Â 100%, where f pressure is the diameter of the vessel at a certain pressure and f 5 mm Hg is the diameter of the vessel at 5 mm Hg.
Percent reactivity to NONOate was calculated as the percent dilation in relation to the highest concentration of NONOate by the equation ([f conc Àf min ]/[f papav Àf min ]] Â 100%, where f conc is the diameter of the vessel at the specific concentration of NONOate, f min is the diameter at the minimal concentration of NONOate, and f papav is the diameter of the vessel fully relaxed by papaverine.
Statistical Analysis
Data are presented as mean + standard error. Comparisons were made between LPS-and vehicle-treated animals by unpaired t test and considered significant at P < .05. No statistical analysis of PCR results was performed as the vessels were from pooled samples and thus no variance was obtained. Table 1 summarizes the physiological parameters and pregnancy outcome data for all groups of animals. There was no difference in blood pressures prior to or after LPS infusion. There was also no difference in blood pressures between NP-CTL and LP-CTL animals. Low-dose LPS treatment had a small effect on pregnancy outcome. The pup weights were lower but nonsignificantly decreased in LP-LPS animals versus LP-CTL, without any change in placental weights. There was also a nonsignificant increase in reabsorptions in these animals. Thus, low-dose LPS treatment during pregnancy had a small yet detectable effect on pregnancy outcome but did not show symptoms of preeclampsia as others have shown. 24 
Results

Maternal Blood Pressure and Pregnancy Outcome With Low-Dose LPS Treatment
Effect of Pregnancy and Low-Dose LPS on Active Myogenic Responses
Posterior cerebral arteries from all groups of animals displayed myogenic reactivity, as noted by the decrease in diameter with increasing pressure. There was no difference in the active response to pressure between NP-CTL and NP-LPS groups ( Figure 1A ). However, pregnant animals treated with LPS had larger diameters at 50, 75, and 100 mm Hg and displayed myogenic reactivity only when the pressure was increased to 125 mm Hg ( Figure 1B ). There was no difference in the amount of tone displayed in PCAs from either of the NP groups ( Figure 1C ). However, the larger active diameters in PCAs from LP-LPS animals were due to significantly decreased pressuredependent tone at those pressures ( Figure 1D ). Thus, low-dose LPS decreased the active myogenic activity in PCAs from pregnant animals only, causing them to have larger lumen diameters.
Effect of Pregnancy and Low-Dose LPS on NO-Mediated Vasodilation and iNOS Expression
Dilation to the NO donor NONOate in the presence of NOS inhibition was used to assess the sensitivity of the smooth muscle in PCAs to NO. Posterior cerebral arteries from all groups of animals dilated to NONOate that was close to maximal dilation at the highest concentration (as compared to papaverine and diltiazem). Lipopolysaccharide treatment of nonpregnant animals did not affect the response of PCAs to NONOate (Figure 2A) . In contrast, PCA from LP-LPS animals were significantly more sensitive to the dilatory effects of NONOate ( Figure 2B ). All vessels constricted in response to L-NNA, suggesting basal NO was present and inhibiting tone ( Figure 2C ). Lipopolysaccharide treatment of both nonpregnant and pregnant animals caused a nonsignificant increase in L-NNAinduced constriction compared to saline-treated controls. Similarly, both groups of pregnant animals had a nonsignificant increase in L-NNA-induced constriction compared to both nonpregnant groups, with PCA from the LP-LPS producing the greatest constriction (P < .05 vs NP-CTL). Thus, both pregnancy and LPS appear to increase the contribution of NO to basal tone. In addition, the increased constriction to L-NNA noted in the LP-LPS groups could be due to an increased sensitivity of the smooth muscle to NO, as noted above with NONOate.
Nitric oxide in the vascular wall can be produced by 3 different NOS enzymes, eNOS, nNOS, and iNOS. 25 While eNOS and nNOS are constitutively expressed, iNOS is not normally expressed in the vasculature but is induced by LPS and other proinflammatory cytokines. 25, 26 Inducible nitric oxide synthase expression mediates vascular dysfunction and loss of contractile function in response to LPS. 26, 27 Thus, we measured the level of iNOS mRNA in cerebral arteries from all groups of animals as this could be responsible for the decreased tone in the LP-LPS vessels due to increased NO production ( Figure 2D ). Posterior cerebral arteries from control pregnant animals had a~3-fold increase in iNOS expression compared to control arteries from nonpregnant animals, suggesting that pregnancy alone has greater iNOS expression in the cerebral vasculature. Lipopolysaccharide treatment caused an increase in iNOS mRNA expression in cerebral arteries from both nonpregnant and pregnant animals. When the level of iNOS mRNA was compared between both LPS-treated groups, arteries from the LP-LPS animals had greater than a 2-fold increase in iNOS compared to arteries from NP-LPS animals. Thus, the greater NO reactivity in arteries from the LPS-treated pregnant animals could be due to increased iNOS in those vessels.
Effect of Pregnancy and Low-Dose LPS on Cerebral Artery Structural Properties
Low-dose LPS has been shown to cause structural remodeling of uterine and renal arteries during pregnancy. 28 We therefore assessed whether LPS had a similar effect on cerebral arteries. Figure 3 shows passive lumen diameters and distensibility at pressures from 5 to 150 mm Hg in PCAs from nonpregnant and late-pregnant animals. Passive diameters of PCA from NP-LPS animals were larger (nonsignificantly) than controls ( Figure  3A ). This was due to low-dose LPS causing an increase in distenstibility in PCAs from those animals ( Figure 3C) and not due to an increase in luminal size. This conclusion is based on the finding that diameters at low pressures ( 20 mm Hg), when distensibility has little influence on diameter, are not different. Low-dose LPS treatment had no effect on passive lumen diameter or distensibility of PCAs from pregnant animals ( Figure 3D ). However, there was a significant increase in wall thickness in PCAs from LP-LPS animals compared to control, suggesting medial hypertrophy occurred in those vessels ( Figure 4B ). There was no effect of LPS on the wall thickness of PCAs from nonpregnant animals ( Figure 4A ). Thus, LPS had a differential effect on passive structural properties between nonpregnant and pregnant animals, whereby it caused an increase in distensibility in the arteries from nonpregnant animals and medial hypertrophy in PCAs from late-pregnant animals.
Effect of Pregnancy and Low-Dose LPS on Cytokine mRNA Expression in the Cerebral Vasculature
It is well known that pregnancy is a state of altered cytokine production 6-8 ; however; how pregnancy affects cytokines in the cerebral circulation that may alter its structure or function is unknown. In addition, the effects of LPS on the vasculature are mediated by production of proinflammatory cytokines that may be different during pregnancy. Thus, we assessed mRNA levels of the proinflammatory cytokines TNF-a and IFN-g in cerebral arteries from all groups of animals. In addition, we also measured mRNA levels of IL-10 as this anti-inflammatory cytokine attenuates many of the inflammatory effects of LPS, including those in the cerebral circulation. 29, 30 Low-dose LPS treatment of nonpregnant animals caused a small increase in IL-10 and a similarly small decrease in TNF-a mRNA expression in PCA but an~3fold increase in IFN-g ( Figure 5A ). In contrast, LPS treatment of pregnant animals caused a decrease in both IL-10 and TNFa, as well as IFN-g in the cerebral vascular wall compared to saline-treated controls ( Figure 5B ). Pregnancy alone also affected cytokine levels in the cerebral vasculature. In control animals, arteries from late-pregnant animals had considerably greater cytokine levels compared to nonpregnant arteries ( Figure 5C ). However, after LPS treatment, there was little difference in the cytokine levels between nonpregnant and late-pregnant arteries. Cerebral arteries from LP-LPS animals had a small decrease in IL-10, a small increase in TNF-a, and a moderate decrease in IFN-g compared to NP-LPS ( Figure 5D ). It should be noted that PCR was done on arteries pooled from 2 to 3 animals to obtain enough sample for all the targets. Thus, these results are somewhat preliminary, and a more indepth study on cytokine expression in the vasculature is needed to extend these results.
Discussion
In the present study, we found that similar to other organs, the cerebral vasculature is more sensitive to the effects of LPS. For example, LPS treatment of pregnant animals caused cerebral arteries to have diminished myogenic tone and increased diameters under active conditions. This enhanced vasodilatory state was likely due to increased NO responsiveness and a greater inhibitory influence of NO on tone as these vessels had increased sensitivity to the NO donor NONOate and increased constriction to NOS inhibition with L-NNA. In addition, arteries from LP-LPS animals had significantly increased wall thickness, suggesting these arteries had medial hypertrophy. In contrast, low-dose LPS had little effect on cerebral arteries from nonpregnant animals. Although LPS treatment of nonpregnant animals caused an increase in passive distensibility of cerebral arteries, this did not seem to affect vascular function. Taken together, it appears that low-dose endotoxin during pregnancy promotes an inflammatory state in the cerebral vasculature that was not seen in similarly treated nonpregnant animals. The effects of LPS on the vasculature may be mediated by induction of proinflammatory cytokines. We therefore measured mRNA levels of the proinflammatory cytokines TNF-a and IFN-g and compared the levels to those from vehicletreated animals. Lipopolysaccharide treatment of nonpregnant animals had little effect on vascular TNF-a but increased IFN-g levels 3-fold ( Figure 5A ). In contrast, cytokine levels in cerebral arteries from pregnant animals treated with LPS were distinctly different with both inflammatory cytokines decreasing substantially ( Figure 5B ). The differential response of the cerebral vasculature to LPS-induced cytokines between nonpregnant and late-pregnant animals may be due to several factors. First, because this measurement was taken 5 days after LPS exposure, the change in cytokine levels may reflect different cell types that are present within the vascular wall and producing the cytokines, eg, trafficking of macrophages through the vascular wall. One limitation of our approach was that we cannot determine what cell type or types are changing their cytokine expression in response to LPS. In addition, the different cell types within the vascular wall may be responding to LPS with different kinetics, that is, measurement at earlier time points may reveal different cytokine responses. Second, the vasculature from pregnant animals appears to be in a different state immunologically prior to LPS exposure and thus may respond differently to LPS than nonpregnant. For example, when we compared cytokine levels in cerebral arteries from vehicle-treated animals, arteries from pregnant animals had a 2-to 4-fold increase in TNF-a and IFN-g compared to nonpregnant animals ( Figure  5C ). Thus, it appears that the cerebral vasculature during pregnancy is in a state of inflammation even prior to LPS exposure which may explain its increased sensitivity to the effects of LPS. Another indication that the cerebral vasculature is in a state of inflammation during pregnancy and with LPS exposure is that iNOS mRNA is elevated in both vehicle-treated controls and after LPS treatment compared to arteries from nonpregnant animals ( Figure 2D ). Although LPS treatment induced iNOS mRNA expression in arteries from both nonpregnant and pregnant animals, the levels were higher in the pregnant arteries. In addition, although LPS treatment increased iNOS expression in arteries from nonpregnant animals, it did not appear to have much effect on vascular function. In contrast, iNOS expression in pregnant arteries was associated with increased constriction to L-NNA and enhanced sensitivity to dilation of the NO donor NONOate. The increased constriction to NOS inhibition with L-NNA in pregnant arteries suggests that there is an enhanced contribution of NO to basal tone that could be due to either an increase in endothelial NO production from eNOS or an increase in sensitivity of the smooth muscle to the effects of NO. Although the results from this study are not conclusive, there was not likely an enhanced effect of eNOS since sensitivity to NONOate was assessed in the presence of NOS inhibition. In addition, several studies have shown that induction of iNOS in cerebral arteries impairs eNOS-dependent relaxation but activates soluble guanylyl cyclase (sGC) in smooth muscle. 31, 32 An increase in sGC after LPS treatment in cerebrovascular smooth muscle could explain the increase in sensitivity to NON-Oate that was noted in pregnant animals, as well as the increased constriction to NOS inhibition.
It is well known that LPS treatment increases iNOS expression in the vasculature, including cerebral arteries, that decreases constrictor responses presumably from the production of large amounts of NO. 27, [33] [34] [35] [36] Gunnett et al showed that LPS treatment of wild-type mice reduced constriction of cerebral arteries that was prevented with pharmacological inhibition of iNOS in iNOS-deficient mice, providing the first direct evidence that iNOS is a critical mediator of reduced contractile function after exposure to LPS. 27 In the present study, we used a microdose of LPS that did not appear to have an effect on contractile function of arteries from nonpregnant animals, but significantly decreased myogenic tone and reactivity to pressure in arteries from pregnant animals. It is likely that the increase in iNOS expression and enhanced effect on NO responsiveness contributes to the decreased tone in the LP-LPS arteries.
While the results from this study are the first to demonstrate that the cerebral vasculature is highly sensitive to the effects of LPS during pregnancy, it is difficult to explain the underlying mechanism by which this occurs. Cytokine production and their effects is complex and may not be the only factor involved in LPS-induced effects. However, one cytokine that may be important for enhancing sensitivity of the cerebral vasculature to the effects of LPS is IL-10. Interleukin 10 is an antiinflammatory cytokine that inhibits production of proinflammatory cytokines such as TNF-a. 37 Interleukin 10-deficient mice are more sensitive to the effects of LPS and have significantly greater impairment of vascular contractile function as wild-type controls. 35 In addition, expression of iNOS in the cerebral vasculature is significantly greater in IL-10-deficient mice compared to wild-type in response to LPS, an effect thought to mediate the enhanced vascular dysfunction in those animals. 35 Interleukin 10 is produced by several cell types including the vasculature and serves to limit the production of proinflammatory cytokines such as TNF-a and iNOS in response to LPS. [38] [39] [40] In the present study, LPS did not appear to affect IL-10 levels in cerebral arteries from nonpregnant animals but decreased IL-10 in arteries from pregnant animals. While it is tempting to speculate that decreased IL-10 in LP-LPS arteries is responsible for the more proinflammatory state of these vessels and enhanced sensitivity to LPS, when we compared IL-10 expression in control arteries, pregnant vessels had a modest increase in IL-10. However, when comparing both nonpregnant and pregnant vessels that had been exposed to LPS ( Figure 5D ), pregnancy was associated with a modest decrease in IL-10 levels. Thus, it appears that IL-10 expression is somewhat increased during pregnancy under control conditions, but its expression is decreased in response to LPS and this may serve to enhance the effects of LPS in those vessels. In addition to a differential effect on cytokines and contractile function, LPS also differentially affected cerebrovascular structure between nonpregnant and pregnant animals.
Lipopolysaccharide treatment of nonpregnant animals caused a significant increase in passive distensibility in cerebral arteries ( Figure 3C ). The increased distensibility in those vessels caused the vessels to have larger lumen diameters at pressures >30 mm Hg ( Figure 3A) . These vessels were not actually larger because diameters were not different at low pressures where there was no influence of distensibility on diameter. In contrast, LPS did not affect distensibility or lumen diameter of PCA from pregnant animals ( Figure 3B and D) but significantly increased wall thickness ( Figure 4B ). Although it is not clear what caused this medial hypertrophy in the pregnant vessels in response to LPS, increased production or sensitivity to cytokines and/or growth factors (that we did not measure because of insufficient sample size) could account for the change in the vascular wall. It is worth noting that some studies , tumor necrosis factor-a (TNF-a), and interferon g (IFN-g). Lipopolysaccharide treatment of nonpregnant animals caused little change in interleukin 10 (IL-10) or TNF-a mRNA of cerebral arteries but increased IFN-g levels of~3-fold (A). In contrast, LPS treatment caused a modest decrease in all cytokine mRNA measured from cerebral arteries (B). When mRNA levels of cytokines were compared in arteries from control nonpregnant and late-pregnant animals, pregnancy alone caused a modest increase in IL-10 and TNF-a and a~4-fold increase in IFN-g (C). Finally, when mRNA from arteries from both LPS groups were compared, there was a small decrease in both IL-10 and IFN-g and a small increase in TNF-a in pregnant animals compared to nonpregnant (D). Arteries were pooled from 2 to 3 animals per group to obtain enough sample to do the RT-PCR. NP-CTL indicates nonpregnant vehicle treated; NP-LPS, nonpregnant treated with LPS; LP-CTL, late-pregnant vehicle treated; LP-LPS, late-pregnant LPS treated; mRNA, messenger RNA.
have shown that the low-dose endotoxin during pregnancy causes preeclamptic-like symptoms including hypertension, proteinuria, and disseminated intravascular coagulation possibly due to the enhanced glomerular inflammatory reaction noted above. 3, 13, 24 Other studies have shown using this model that it was associated with proteinuria and thrombocytopenia but not hypertension. 28 This same study found that low-dose endotoxin administration to pregnant rats caused increased media thickness of the arteries from the placenta and kidney that was not due to elevated mean arterial pressure. In the present study, we also did not find that low-dose endotoxin during pregnancy caused preeclamptic-like symptoms, but cerebral arteries did undergo medial hypertrophy similar to uterine and renal arteries noted in other studies.
In summary, here we show for the first time that cerebral arteries during pregnancy appear to be in a state of inflammation that is associated with increased sensitivity to the effects of LPS, with increased iNOS and proinflammatory cytokine expression and decreased myogenic tone. However, what effect this may have on the brain during pregnancy and/or in response to LPS is not clear. Vascular dysfunction in response to LPS is thought to be pathological and causes the vascular collapse associated with sepsis. If similar events happen in the brain, it could decrease vascular resistance and impair autoregulation that could promote edema formation and neurological complications such as those during severe preeclampsia (headache, visual disturbances, uncontrolled vomiting, and seizure). However, how good of a model the low-dose LPS is for preeclamspia and eclampsia is not clear, as women with infection seem protected from neurological complications. This suggests that innate immune system activation during pregnancy and preeclampsia is a complex process that requires further investigation, especially with regard to how it affects the brain and its vasculature.
